From Analysis:
Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia
Which clinical, genetic, and biomarker features are independent prognostic markers for time-to-dementia in cognitively impaired individuals?
This hypothesis proposes that mitochondrial dysfunction represents a primary pathogenic mechanism in Alzheimer's disease, operating through impaired ATP synthesis and increased oxidative stress that precedes and drives amyloid-beta accumulation. Specifically, mutations or age-related damage to TFAM (Transcription Factor A, Mitochondrial) lead to defective mitochondrial DNA replication and reduced expression of respiratory chain complexes I and IV. This mitochondrial impairment creates a bioenergetic crisis in neurons, particularly affecting synaptic transmission which requires high ATP levels. The resulting energy deficit triggers compensatory upregulation of APP processing through the amyloidogenic pathway as neurons attempt to maintain cellular homeostasis.
...No AI visual card yet
Curated pathway diagram from expert analysis
graph TD A[APOE4] --> B[ABCA1]
Median TPM across 13 brain regions for TFAM from GTEx v10.
Title: Baseline Executive Function Deficits Predict Faster Dementia Progression via Prefrontal-Subcortical Circuit Disruption
Description: Impaired executive function (EF) at baseline independently accelerates dementia onset in MCI beyond memory deficits. The mechanism involves disruption of frontostriatal circuits governing attentional control and behavioral regulation—these networks are particularly vulnerable to small vessel di
The user wants me to critically evaluate four hypotheses about time-to-dementia predictors in cognitively impaired individuals. I need to be rigorous, identify weaknesses, cite counter-evidence, propose falsification experiments, and provide revised confidence scores.
Let me work through each hypothesis systematically.
Hypothesis 1: Executive Dysfunction as Independent Clinical Marker
The claim is that baseline EF deficits independently accelerate dementia onset beyond memory deficits, via prefrontal-subcortical circuit disruption.
Strengths:
Claim: EF deficits independently accelerate dementia onset via frontostriatal disruption, bypassing hippocampal mechanisms.
Critical Weaknesses:
| Issue | Explanation |
|-------|-------------|
| Baseline severity confound | EF deficits at baseline may reflect disease stage, not intrinsic velocity. If a patient presents with worse EF and worse memory, they may simply be further along—predicting c
{"ranked_hypotheses":[{"title":"APOE ε4 Carriage as Primary Genetic Determinant of Dementia Progression Velocity","description":"APOE ε4 remains the strongest validated predictor of time-to-dementia in MCI, operating through multiple pathways including Aβ aggregation, microglial activation, synaptic vulnerability, tau spreading, and vascular dysfunction. Despite critiques regarding amyloid-centric framing and survival bias at the MCI stage, the evidence base is unmatched. The hypothesis survives falsification in amyloid-negative cohorts and across diverse populations. Composite score integra
No price history recorded yet
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for TFAM.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
APOE__4["APOE ε4"] -->|causes| A__aggregation["Aβ aggregation"]
APOE__4_1["APOE ε4"] -->|causes| tau_spreading["tau spreading"]
APOE__4_2["APOE ε4"] -->|causes| cortical_A__burden["cortical Aβ burden"]
APOE__4_3["APOE ε4"] -->|risk factor for| AD["AD"]
hippocampal_atrophy_rate["hippocampal atrophy rate"] -->|predicts| dementia_conversion["dementia conversion"]
hippocampal_atrophy_rate_4["hippocampal atrophy rate"] -->|modulates| APOE__4_risk["APOE ε4 risk"]
CSF_NfL["CSF NfL"] -->|indicates| axonal_injury["axonal injury"]
APOE__4_5["APOE ε4"] -->|causes| microglial_activation["microglial activation"]
APOE__4_6["APOE ε4"] -->|causes| synaptic_vulnerability["synaptic vulnerability"]
APOE__4_7["APOE ε4"] -->|causes| vascular_dysfunction["vascular dysfunction"]
A_["Aβ"] -->|causes| hippocampal_atrophy["hippocampal atrophy"]
tau["tau"] -->|causes| hippocampal_atrophy_8["hippocampal atrophy"]
style APOE__4 fill:#ce93d8,stroke:#333,color:#000
style A__aggregation fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_1 fill:#ce93d8,stroke:#333,color:#000
style tau_spreading fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_2 fill:#ce93d8,stroke:#333,color:#000
style cortical_A__burden fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_3 fill:#ce93d8,stroke:#333,color:#000
style AD fill:#ef5350,stroke:#333,color:#000
style hippocampal_atrophy_rate fill:#4fc3f7,stroke:#333,color:#000
style dementia_conversion fill:#4fc3f7,stroke:#333,color:#000
style hippocampal_atrophy_rate_4 fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_risk fill:#4fc3f7,stroke:#333,color:#000
style CSF_NfL fill:#4fc3f7,stroke:#333,color:#000
style axonal_injury fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_5 fill:#ce93d8,stroke:#333,color:#000
style microglial_activation fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_6 fill:#ce93d8,stroke:#333,color:#000
style synaptic_vulnerability fill:#4fc3f7,stroke:#333,color:#000
style APOE__4_7 fill:#ce93d8,stroke:#333,color:#000
style vascular_dysfunction fill:#4fc3f7,stroke:#333,color:#000
style A_ fill:#4fc3f7,stroke:#333,color:#000
style hippocampal_atrophy fill:#4fc3f7,stroke:#333,color:#000
style tau fill:#4fc3f7,stroke:#333,color:#000
style hippocampal_atrophy_8 fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-16 | completed
No comments yet. Be the first to comment!